[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cardarelli Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,75,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100639913","use-of-d-chiro-inositol-in-male-functional-hypogonadism-associated-with-sexual-dysfunction-100639913",false,"NCT07584772","Use of D-Chiro-inositol in Male Functional Hypogonadism Associated With Sexual Dysfunction","HERO_2025","Inclusion Criteria:\n\n* Men aged between 50 and 75\n* Affected by functional hypogonadism associated with male aging\n\nExclusion Criteria:\n\n* Elevated ferritin, PRL, and\u002For elevated CRP values; diagnosis of primary hypogonadism; diagnosis of organic hypogonadotropic hypogonadism or secondary to other ongoing acute or chronic pathologies; presence of other pituitary deficits.\n* Alcohol use and\u002For drug abuse, recent hormone treatment, smoking, systemic or endocrine diseases, infection of the male accessory glands, medical history of cryptorchidism or varicocele, and micro-orchidism.","MALE","50 Years","75 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","A prospective, uncontrolled, non-pharmacological interventional study conducted on men with functional or borderline hypogonadism, aimed at evaluating, after 3 months of supplementation with D-Chiro-inositol, changes in hormonal profile and sexual function.",[27],"Functional Hypogonadism","NOT_YET_RECRUITING","2026-05-07",{"date":31,"type":32},"2026-05-13","ACTUAL",{"date":34,"type":21},"2026-07-01",{"date":36,"type":21},"2027-01-01",{"name":38,"class":39},"Cardarelli Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":18,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100615690","topical-nifedipine-03-plus-lidocaine-15-for-uncomplicated-hemorrhoidal-disease-100615690","NCT07295886","Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease","Observational Study on the Use of Topical Nifedipine 0.3% and Lidocaine 1.5% in Acute Uncomplicated Hemorrhoidal Disease","NILOS","Inclusion Criteria:\n\n* Male and female patients aged 18-75 years.\n* Clinical or anoscopic diagnosis of acute hemorrhoidal disease with prolapse severity between Grade II and IV (Goligher), possibly associated with external congestion.\n* Patients who started treatment with nifedipine 0.3% + lidocaine 1.5% within the past 5 days.\n* Availability of clinical evaluations at treatment initiation (proctologic visit and HDSS, SHS-HD, VAS scales).\n* Ability to understand the informed consent.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Acute hemorrhoidal disease complicated by thrombosis or strangulation.\n* Coagulopathies.\n* Active neoplastic disease.\n* Treatment with anticoagulants and\u002For chemotherapeutic agents.\n* Hypersensitivity to active substances, especially lidocaine (and other amide-type local anesthetics) or excipients.\n* Severe hypotensive states or cardiovascular insufficiency.\n* Pregnancy or breastfeeding.\n* Participation in clinical trials involving investigational drugs.","ALL","18 Years",{"count":51,"type":21},80,"30 Days","OBSERVATIONAL","The goal of this observational study is to evaluate the effectiveness of topical nifedipine 0.3% plus lidocaine 1.5% for uncomplicated hemorrhoidal disease. The main question it aims to answer is:\n\nDoes topical nifedipine 0.3% plus lidocaine 1.5% lower symptoms in patients with uncomplicated acute hemorrhoidal disease? Participants already taking nifedipine 0.3% plus lidocaine 1.5% as part of their regular medical care for hemorrhoidal disease will undergo four visits over a 30-day period, including two telephone contacts and two in-person visits.",[56,57,58,59,60],"Hemorrhoid Bleeding","Hemorrhoids Prolapse","Hemorrhoid Pain","Hemorrhoid","Topical Administration",[62,63,64],"nifedipine 0.3% plus lidocaine 1.5%","uncomplicated hemorrhoidal disease","hemorrhoids symptoms","RECRUITING","2025-12-19",{"date":68,"type":32},"2025-12-22",{"date":70,"type":32},"2025-09-02",{"date":72,"type":21},"2026-05-02",{"name":38,"class":39},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":53,"phases":4,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":74},"100580464","during-chest-surgery-one-lung-is-isolated-from-ventilation-to-improve-visibility-with-carbon-dioxide-introduced-between-the-lung-and-chest-wall-capnothorax-the-study-seeks-to-optimize-ventilation-through-esophageal-pressure-measurement-reducing-respiratory-complications-100580464","NCT06837636","During Chest Surgery, One Lung is Isolated From Ventilation to Improve Visibility, With Carbon Dioxide Introduced Between the Lung and Chest Wall (Capnothorax): the Study Seeks to Optimize Ventilation Through Esophageal Pressure Measurement, Reducing Respiratory Complications.","The Use of Esophageal Pressure as a Guide to Set One Lung Ventilation During Capnothorax.","CapnoPes","Inclusion Criteria:\n\n* Age over 18 years • Patients to undergo robotic thoracic surgery with capnothorax\n\nExclusion Criteria:\n\n* Pre-existing cardiac and\u002For pulmonary pathologies resulting in an ASA \\> 3\n\n  * Contraindications to the placement of a nasogastric tube\n  * Severe COPD (stage 3 or 4)\n  * Emergency thoracotomy or sternotomy for surgical complications",{"count":84,"type":21},36,"2 Weeks","The objective of this single-center observational study is to improve the safety and effectiveness of chest surgery through the use of a new ventilation technique. During the operation, to allow the surgeon to work more precisely, only one lung will receive air from the respirator. To improve visibility during surgery, a small amount of carbon dioxide is introduced into the space between the lung and the chest wall, a procedure called capnothorax. The aim of the research is to find the best way to set the patient's ventilation during the operation, ensuring adequate oxygenation and minimizing the risks to the lung. To do this, we will use a method of measuring the pressure inside the esophagus, which will allow us to better understand the status of the lungs and adjust ventilation accordingly. Esophageal pressure is an indirect measure of the pressure within the lung. By measuring this pressure, we can get important information about the status of the lungs and their ability to expand and contract. By measuring esophageal pressure, researchers will be able to set ventilation more precisely, optimizing the amount of air that is supplied to the lungs and the pressure inside the lungs themselves. This could help prevent lung damage and improve the patient's breathing during and after surgery, reducing respiratory complications and improving patients' quality of life.\n\nGeneral data collected at the beginning of the study and before the surgical intervention:\n\n* date of birth, gender, weight, and height,\n* information and scores regarding the fitness for general anesthesia techniques,\n* anesthesia risk assessment made by the American Society of Anesthesiologists (ASA),\n* data related to respiratory mechanics.\n\nData collected during the surgical intervention:\n\n* data related to respiratory mechanics measured at the ventilator,\n* data recorded by the optivent monitor to which the esophageal probe is connected,\n* hemodynamic data collected through a semi-invasive arterial blood pressure monitoring system,\n* arterial blood gas analysis,\n* pulmonary ultrasound findings.",[88,89,90,91],"Capnothorax","One Lung Ventilation","Thoracic Surgery","Esophageal Pressure Measurement",[93,94,95,96],"capnothorax","one lung ventilation","esophageal pressure","thoracic surgery","2025-02-23",{"date":99,"type":32},"2025-02-25",{"date":101,"type":21},"2025-02-20",{"date":103,"type":21},"2026-03",{"name":38,"class":39},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":74},"100549814","nbi-for-early-diagnosis-of-opmdoscc-100549814","NCT06438939","NBI for Early Diagnosis of OPMD\u002FOSCC","Narrow Band Imaging (NBI) for Early Diagnosis of Oral Squamous Cell Carcinoma (OSCC) and Oral Potentially Malignant Disorders (OPMD)","NBI_Oral","Inclusion Criteria:\n\n* Patients with soft tissue, mucosal lesions of the oral cavity, who arrive for an initial first diagnosis (group 1);\n* Patients with history OPMD (clinically evident lesion\u002Fs group 2a, lesion\u002Fs excised group 2b), who are in follow-up (OPMDs included are eg. Leukoplakia, erythroleukoplakia, erythroplakia, oral lichen planus, oral lichenoid lesion);\n* Patients with history of HNSCC (OSCC group 3a, sinonasal, nasopharynx, oropharynx, larynx, oesophagus group 3b);\n* High risk (see above) individuals with no known oral mucosal disease (group 4);\n\nExclusion Criteria:\n\n* patients who did not need a biopsy nor after WLOE (e.g. normal mucosa, anatomical variation) nor after NBI (pattern I)\n* patients who, despite indication, were not suitable to undergo biopsy given his \u002F her systemic conditions",{"count":114,"type":21},480,[24],"Early detection - possibly at its pre-malignant stages (Oral Potentially Malignant Disorders, OPMD) - with periodic surveillance is thus fundamental for limiting disease burden, hopefully reducing the incidence of advanced stages OSCC and increasing survival. Narrow Band Imaging (NBI) has proved itself as promising tool for helping clinician both for diagnosis and therapy. Yet, there is no definitive scientific evidence that NBI is superior to common oral examination with white light (WLOE) for diagnosing OSCC\u002FOPMD. We thus propose a randomised clinical trial understand its role in this field.",[118,119],"Oral Squamous Cell Carcinoma","Oral Potentially Malignant Disorder",[121,122,123,124],"narrow band imaging","OSCC","OPMD","NBI","2024-05-27",{"date":127,"type":32},"2024-06-03",{"date":129,"type":21},"2024-09-30",{"date":131,"type":21},"2026-12-31",{"name":38,"class":39},""]